In brief
A surge of public discontent in China regarding the perceived ineffectiveness of generic drugs has prompted government action amidst ongoing concerns about the healthcare system’s capacity to manage an aging population and rising costs.
Public discontent in China has erupted over fears that generic drugs being used in public hospitals are failing to meet efficacy standards, prompting an unusual response from the government. Doctors attribute the growing concerns to the drug procurement system that favors low-cost generic medications, leading to compromises in patient safety. In contrast, officials have dismissed allegations of ineffectiveness as largely anecdotal, arguing that perceptions vary among individuals. Nevertheless, this response has failed to soothe public anxieties regarding the quality of medications in state-run healthcare facilities.The controversy gained traction in December following the announcement of a procurement list featuring nearly 200 domestic makers of generic drugs. This was exacerbated in January by a viral video of Zheng Minhua, a Shanghai hospital director, who highlighted several troubling instances with generic medications, including ineffective antibiotics and laxatives. Zheng's remarks resonated widely, leading to discussions on social platforms, although censorship efforts have sought to limit this discourse.Several patients have come forward to share negative experiences associated with these generic prescriptions, expressing skepticism about their effectiveness compared to brand-name counterparts. A user on Xiaohongshu urged others to verify drug brands before purchasing, reinforcing the belief that generic versions might not offer true relief.The procurement system, established in 2018, aims to cut public healthcare costs by allowing local governments to solicit the lowest bids for essential medications. While this system has allegedly saved patients over $50 billion, it has also raised concerns about the sustainability of low-priced drugs. Experts caution that such pricing could compel manufacturers to skimp on quality, resulting in potentially ineffective medications.Amidst these troubles, questions have also arisen about the reliability of data used to approve generic drugs for procurement—specifically, claims that trial data mirrored original drug data closely. These allegations drove some medical professionals to speak out, but the response from authorities has been criticized as insufficient.As healthcare funding faces increasing strain from China’s rapidly aging population—leading to a twentyfold increase in health expenditure over two decades—the need for reform, transparency, and improved quality standards has become crucial. While the state has begun to acknowledge these challenges, the effectiveness of its proposed remedies remains uncertain, against the backdrop of skepticism and public outcry for accountability in the nation's pharmaceutical practices.
